Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;190(3):e150-e154.
doi: 10.1111/bjh.16961. Epub 2020 Jul 16.

Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome

Ryan L Hoiland  1   2 , Sophie Stukas  3 , Jennifer Cooper  3 , Sonny Thiara  4 , Luke Y C Chen  5 , Catherine M Biggs  6 , Kevin Hay  5 , Agnes Y Y Lee  5 , Kamran Shojania  7 , Alym Abdulla  5 , Cheryl L Wellington  3 , Mypinder S Sekhon  4
Affiliations

Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome

Ryan L Hoiland et al. Br J Haematol. 2020 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts financial or otherwise.

Figures

Fig 1
Fig 1
Tocilizumab reduces the concentration of circulating serum inflammatory cytokines and clinical laboratory variables. Top panel (A–D): levels of serum interleukin (IL)‐1β, IL‐6, IL‐10 and tumour necrosis factor alpha (TNF‐α) for each patient. Vertical dashed lines represent the timing of tocilizumab administration relative to daily measurements of cytokines. Bottom Panel (E–H): levels for lymphocyte count, C‐reactive protein, ferritin and D‐dimer for each patient. Vertical dashed lines represent the timing of tocilizumab administration relative to daily measurements of clinical laboratory value. *denotes a significant difference from Day 0, P < 0·05.
Fig 2
Fig 2
Changes in cardiorespiratory function following tocilizumab. The PaO2/FiO2 ratio, mean arterial pressure (MAP), and noradrenaline dose prior to and following tocilizumab administration. For panels A–C, the physiological variable is displayed on the y‐axis with corresponding units, while days after tocilizumab administration are on the x‐axis. Chest X‐rays are presented for two patients within 24‐h prior to drug administration and then 24–48 h and 72–96 h following drug administration. Individual IL‐6 and PaO2/FiO2 (P/F) ratio data are displayed. For the patient on the left, note that tocilizumab treatment lead to radiographic improvement, despite persistently high inflammation (IL‐6 >3400 pg/ml for all time points). This patient has been discharged home. The patient on the right required VV‐ECMO for refractory hypoxaemia. Tocilizumab led to radiographic improvement in this patient, who has been discharged home. PaO2, partial pressure of arterial oxygen; FIO2, fraction of inspired oxygen. *denotes a significant difference from Day 0, P < 0·05.
See this image and copyright information in PMC

References

    1. England JT, Abdulla A, Biggs CM, Lee AY, Hay KA, Hoiland RL, et al. Weathering the COVID‐19 storm: lessons from hematologic cytokine syndromes. Blood Rev. 2020;15:100707. - PMC - PubMed
    1. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID‐19 in Wuhan, China. Clin Infect Dis. 2020. [Epub ahead of print]. 10.1093/cid/ciaa248 - DOI - PMC - PubMed
    1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features in severe and moderate Coronavirus Disease 2019. J Clin Invest. 2020;130:2620–9. - PMC - PubMed
    1. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020. [Epub ahead of print]. 10.1093/cid/ciaa272 - DOI - PMC - PubMed
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed

Publication types

MeSH terms